Hims & Hers rallies after announcing plans to enter Canada

Hims & Hers Health announced plans to bring its weight loss program to Canada following the recent closing of the Zava acquisition. The company said, “Almost two thirds of adults in Canada are overweight or living with obesity, yet access to proven treatments remains limited due to high costs and availability…Hims & Hers plans to offer access to lower-cost treatment options through its digital platform, paired with 24/7 access to licensed providers and personalized, clinically backed care plans. In Canada, branded semaglutide with no surrounding clinical support currently costs more than C$200 a month. The price for generic semaglutide is expected to be available at a significant discount to the branded versions, with the prices expected to lower over time.” The plans for Canada entry “reflect continued progress on a clear growth roadmap, leveraging both organic growth and strategic investments to expand category leadership and global reach,” added Hims & Hers. The stock in morning trading is up 3%, or $1.43, to $50.39.